A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia
Naveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, Jorge Cortes, Gautam Borthakur, Kate Newberry, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Sara Dellasala, Sherry Pierce, Srdan Verstovsek, Naveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, Jorge Cortes, Gautam Borthakur, Kate Newberry, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Sara Dellasala, Sherry Pierce, Srdan Verstovsek
Abstract
Background: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis.
Patients and methods: We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1).
Results: The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58%). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d.
Conclusion: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.
Trial registration: ClinicalTrials.gov NCT01251965.
Keywords: Acute myelogenous leukemia; Clinical study; JAK2V617 mutation; Janus kinase inhibitor; Myelofibrosis; Ruxolitinib.
Conflict of interest statement
Author Disclosures/Conflicts: JC, FR, and SV have received research support from Incyte Corporation for conduct of clinical research studies.
Copyright © 2015 Elsevier Inc. All rights reserved.
Figures
Source: PubMed